### **CHRISTINE FERRO**

Principal

christine.ferro@milliman.com +1 646 473 3427



## **Current Responsibility**

Christine Ferro is a principal and a senior healthcare data analytics consultant in the New York-Atlanta office, where she has worked since 1998. She consults to a wide variety of life science and policy organizations for HEOR and population health analyses.

She currently manages teams of analysts performing cross-sectional and longitudinal data studies. Projects involve client data from various platforms, as well as publicly available databases such as Centers for Medicare & Medicaid Services' (CMS) 100% Research Identifiable Files, Truven's MarketScan, and the CMS Medicare 5% and 100% sample databases.

## **Professional Work Experience**

Christine has extensive experience in data mining, large database management, and analytics. She is an expert in using complex SAS and SQL programming to evaluate and explore data, develop unique models, and perform predictive analytics.

She has provided consulting services to a wide range of clients, including health plans, hospitals and providers, research organizations, insurance companies, and pharmaceutical companies.

HEOR projects have included studies on oncology, mortality, chronic kidney, and circulatory diseases. Projects dealing with population health and therapeutics have included longitudinal studies on the cost of Hepatitis C, multiple sclerosis, oncology, minimally invasive surgery, and pregnancy. Christine has worked on benchmarking insurer and provider claims data using national average and well-managed standards. She has helped develop best practice standards using large administrative databases.

Christine's work on episode-based payment projects have included the CMS's Bundled Payments for Care Improvement initiative, the Comprehensive Care for Joint Replacement program, and the CMMI Oncology Care Management model.

# **Professional Designations**

Certified Healthcare Financial Professional (CHFP)

### Education

BA, Economics, Statistics minor, Rutgers University, 1998

#### **Presentations and Publications**

Berner T, Ferro C, Dieguez G, Metz S, Moore J, Szabo E, Kovesdy CP. Real-World Phosphate Binder Use Among Dialysis-Dependent Patients With CKD. Nephron. 2023 Mar 30. doi: 10.1159/000530230. Epub ahead of print. PMID: 36996774.

McKay RR, Hafron JM, Ferro C, Wilfehrt HM, Fitch K, Flanders SC, Fabrizio MD, Schweizer MT. A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. Adv Ther. 2020 Dec;37(12):4910-4929. doi: 10.1007/s12325-020-01509-5. Epub 2020 Oct 7. PMID: 33029725; PMCID: PMC7596004.

Pulgar S, Bains S, Gooch J, Chambers H, Noritz GH, Wright E, Sawhney TG, Pyenson B, Ferro C. Prevalence, Patterns, and Cost of Care for Children with Cerebral Palsy Enrolled in Medicaid Managed Care. J Manag Care Spec Pharm. 2019 Jul;25(7):817-822. doi: 10.18553/jmcp.2019.25.7.817. PMID: 31232210; PMCID: PMC10398069.

Pyenson BS, Dieguez G, Ferro C, Mavinkurve M, Gonzalez YS. Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines. Am Health Drug Benefits. 2018 Feb;11(1):30-37. PMID: 29692878; PMCID: PMC5902763.

Hafron JM, Wilfehrt HM, Ferro C, Harmon M, Flanders SC, McKay RR. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents. Adv Ther. 2022 Jun;39(6):2515-2532. doi: 10.1007/s12325-022-02085-6. Epub 2022 Mar 30. PMID: 35352309; PMCID: PMC9123060.

Ferro C, Pyenson BS, Lau J, Kelkar M, Phillips N, Lu CW, Yeung P, Bachmann G. The Prevalence and Payer Costs of Potentially Avoidable Emergent Care Visits for Suspected Amniotic Membrane Rupture in Pregnant Women. Am Health Drug Benefits. 2018 Jul;11(5):241-250. PMID: 30464792; PMCID: PMC6207302.

